帯状疱疹ワクチン(Herpes Zoster vaccine)の世界市場機会分析...市場調査レポートについてご紹介

【英文タイトル】MarketVIEW: Herpes Zoster (adult) vaccines
Global vaccine commercial opportunity assessment

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

★目次PDFファイル⇒http://h-and-i.main.jp/market-report/Vaczine/VAMV054_TOC.pdf

[Contents – Summary presentation (MS PowerPoint based)]
PAGES: 62 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Author’s note
Executive Summary
Commercial model key outputs
Herpes zoster vaccines: forecast revenues ($m) to 2030 (HI)
Herpes zoster vaccines: forecast volume (000 doses) to 2030 (HI)
Herpes zoster vaccines: volume (000s doses) and revenue ($m) by population to 2030 (HI)
Herpes zoster vaccines: volume (000s doses) by population and vaccine to 2030 (HI)
Herpes zoster vaccines: volume (000s doses) and revenue ($m) by country to 2030 (HI)
Herpes zoster vaccines: market share volume and revenue by country to 2030 (HI)
Herpes zoster vaccines: forecast revenues ($m) to 2030 (scenarios)
Commercial model key inputs
Age ranges/countries modelled
Existing vaccinees and penetration
Vaccine pricing
Market share – competitor zoster vaccines
Public/private split
Other model considerations
Varicella-zoster virus and herpes zoster (shingles): disease background
Varicella-zoster virus
Varicella-zoster virus – transmission and manifestations
Herpes zoster (shingles)
Presentation and symptoms of herpes zoster
Course of herpes zoster.
Complications of herpes zoster – post-herpetic neuralgia.
Other complications of herpes zoster.
Recurrence of herpes zoster.
Hope-Simpson’s theory on the pathogenesis of herpes zoster
Herpes zoster and stroke risk
Theory of herpes zoster pathogenesis illustrated
VZV and herpes zoster prevalence
Herpes zoster incidence rates.
Incidence of herpes zoster is similar across Europe.
Effect of age and gender on incidence of herpes zoster
Focus on LATAM region
Economic burden of herpes zoster (1)
Economic burden of herpes zoster (2)
Medical management of herpes zoster in immunocompetent people – antiviral therapy
Medical management of herpes zoster in immunocompetent people – supplementary therapy.
Medical management of herpes zoster in immunocompromised patients and special groups
Herpes zoster vaccine – current product Zostavax
Rationale for vaccination against herpes zoster
Zostavax – formulation and development.
The Shingles Prevention Study – design and efficacy
Shingles Prevention Study – long-term efficacy of Zostavax and immunology.
Zostavax in people aged 50–59 years: ZEST study.
Safety of Zostavax
Licensing history of Zostavax
Cost-effectiveness of Zostavax
Recommendations for herpes zoster vaccination.
Zostavax uptake
Reasons for poor uptake of Zostavax
Zostavax sales data – Merck & Co.
Zostavax and the UK
Herpes zoster vaccine – overview of current R&D
Rationale to develop improved herpes zoster vaccines
V212 (ZVHT): a heat-treated zoster vaccine
HZ/su (GSK1437173A): a developmental vaccine from GlaxoSmithKline
Phase III studies of HZ/su (GSK1437173A) in general population
Phase III studies of HZ/su (GSK1437173A) in special populations
New Herpes zoster vaccine: commercial considerations
New Herpes zoster vaccine: target product profile
Assumptions on future licensing of zoster vaccines
Assumptions on the future of the zoster vaccine market
Disclaimer

[Contents – Vaccine demand model(s) (MS Excel-based) – 2 models (HI/LO scenarios)]
WORKSHEETS: ~50

Title sheet
Charts – Total Vol and Val
Charts – Vol and Val by population
Charts – Vol and Val by country
Charts – market share
Vol and Val vaccine and pop
Vol val by country
Vol and val general younger
Vol and val immunocompromised
USA >60 yrs
USA 50-59 yrs
USA >60 yrs immunocompromised
CANADA >60 yrs
CANADA 50-59 yrs
CANADA >60 yrs immunocompromised
FRANCE >60 yrs
FRANCE 50-59 yrs
FRANCE >60 yrs immunocompromised
UNITED KINGDOM >60 yrs
UNITED KINGDOM 50-59 yrs
UNITED KINGDOM >60 yrs immunocompromised
GERMANY >60 yrs
GERMANY 50-59 yrs
GERMANY >60 yrs immunocompromised
ITALY >60 yrs
ITALY 50-59 yrs
ITALY >60 yrs immunocompromised
SPAIN >60 yrs
SPAIN 50-59 yrs
SPAIN >60 yrs immunocompromised
BRAZIL >60 yrs
BRAZIL 50-59 yrs
BRAZIL >60 yrs immunocompromised
ARGENTINA >60 yrs
ARGENTINA 50-59 yrs
ARGENTINA >60 yrs immunocompromised
MEXICO >60 yrs
MEXICO 50-59 yrs
MEXICO >60 yrs immunocompromised
Populations


【レポート販売概要】

■ タイトル:帯状疱疹ワクチン(Herpes Zoster vaccine)の世界市場機会分析
■ 英文:MarketVIEW: Herpes Zoster (adult) vaccines
Global vaccine commercial opportunity assessment
■ 発行日:2014年10月
■ 調査会社:VacZine Analytics
■ 商品コード:VAMV054-2014
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。